SAB-185 is een therapeutisch humaan polyklonaal antilichaam dat levend SARS-CoV-2 krachtig neutraliseert bij titers die 4x hoger zijn dan herstellend plasma

Gegevens suggereren dat SAB-185 een effectief therapeutisch middel kan zijn tegen huidige en muterende virusstammen

Op schema om in de vroege zomer van 2020 klinische proeven te starten voor mogelijke COVID-19-therapie

SIOUX FALLS, SD– (BUSINESS WIRE) – SAB Biotherapeutics (SAB), een klinisch stadium biofarmaceutisch bedrijf met een gepatenteerde technologie om volledig menselijke polyklonale antilichamen te produceren zonder de noodzaak van menselijke plasmadonoren, kondigde vandaag in vitro gegevens aan die aantonen dat SAB-185 , zijn therapeutische kandidaat voor COVID-19, heeft zeer krachtige neutraliserende antilichamen tegen SARS-CoV-2 die vier keer hoger zijn dan het krachtigste geëvalueerde humane plasma-serum serum. Het bedrijf kondigde ook aan dat het op 25 mei met de productie van SAB-185 is begonnen ter ondersteuning van de volgende fase van klinische ontwikkeling voor zijn potentiële COVID-19-therapeuticum, dat nog steeds op schema ligt om in de vroege zomer met menselijke proeven te beginnen.

SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate

SAB-185 is a human polyclonal antibody therapeutic that potently neutralizes live SARS-CoV-2 at titers 4X higher than convalescent plasma

Data suggests that SAB-185 may be an effective therapeutic against current and mutating strains of the virus

On-track to initiate clinical trials for potential COVID-19 therapeutic in early summer 2020

SIOUX FALLS, S.D.–(BUSINESS WIRE)– SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced in vitro data demonstrating that SAB-185, its COVID-19 therapeutic candidate, has highly-potent neutralizing antibodies to SARS-CoV-2 that are four times higher than the most potent human convalescent plasma serum sample evaluated. The company also announced that they initiated manufacturing of SAB-185 on May 25 to support the next phase of clinical development for its potential COVID-19 therapeutic, still on track to begin human trials in early summer.

“These data indicate this human polyclonal antibody therapeutic has potent neutralizing activity against live SARS-CoV-2. The neutralizing titers of SAB-185 are significantly higher than those of the most potent plasma of recovered COVID-19 patients we’ve been able to source,” said William B. Klimstra, PhD Associate Professor of Microbiology and Molecular Genetics, Associate Professor of Immunology and Member of the Center for Vaccine Research at The University of Pittsburgh. “We are still in the early stages of evaluating SAB-185, but the preliminary results are promising. My laboratory is conducting a series of studies to bring SAB-185 into clinical trials as soon as possible.”

“In just seven weeks, we’ve accelerated development of a specifically targeted natural human polyclonal therapeutic, without the need for human serum, and generated large volumes of highly-potent neutralizing antibodies to SARS-CoV-2, to produce clinical lots of our COVID-19 therapeutic candidate, SAB-185,” said Eddie J. Sullivan, PhD, President, CEO and Co-founder of SAB Biotherapeutics. “Consistent with data across SAB’s platform in other indications, these data suggest that our potential COVID-19 therapeutic may remain effective even as SARS-CoV-2 continues to evolve. SAB-185, which was developed from the original Wuhan strain sequences, demonstrated highly-potent neutralizing titers to the mutated Munich strain of the virus, believed to be most prevalent strain in the U.S.,” added Sullivan. “These data give us great confidence as we begin manufacturing clinical product and prepare to move forward in the regulatory pathway to provide a potential solution to combat COVID-19.”

SAB’s novel approach, leveraging genetically engineered cattle to produce fully human antibodies, enables a scalable and reliable production of targeted, higher potency neutralizing antibody product than has been previously possible. As a fully human polyclonal antibody, SAB’s novel therapeutic candidate for COVID-19 deploys the same natural immune response to fight the disease as recovered patients, but with a much higher concentration of targeted antibodies.

Data from SAB’s clinical trials in MERS coronavirus and other infectious disease targets have demonstrated the inherent optimal therapeutic properties of human polyclonal antibodies, including reduced immunogenicity and extended half-life, which point to the potential of this therapeutic approach for both treatment and prophylaxis.

“SAB Biotherapeutics has a successful preclinical track having developed more than a dozen effective antibodies from our DiversitAb™ platform in response to emerging infectious diseases during outbreaks of Ebola, Zika, Dengue, Hantavirus, and others,” said Sullivan. “A highly-potent, polyclonal antibody therapy for COVID-19, could prove critical in combatting this pandemic as it could potentially treat severely ill patients and provide protective antibodies for front-line responders, mission-critical staff, and high-risk populations, such as the elderly and immune compromised.”

About SAB Biotherapeutics, Inc.:

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, highly-targeted, high-potency, human polyclonal immunotherapies at commercial scale. SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19, is being developed in collaboration with CSL Behring and initial funding up to $9.4 million supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services through an existing Rapid Response contract with the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO – CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB).The company is advancing programs in autoimmunity, infectious diseases, inflammation and oncology. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005477/en/

Contacts

Melissa Ullerich

Tel: 605-679-4609

mullerich@sabbiotherapeutics.com

Sean Leous

ICR Inc.

Tel: 646-866-4012

sean.leous@icrinc.com